Brief Behavioural Economic Intervention for Smoking Cessation
Launched by THE UNIVERSITY OF HONG KONG · Jun 4, 2024
Trial Information
Current as of September 10, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to see if a short and simple behavioral intervention can help people stop smoking. The researchers want to find out if this approach can encourage smokers in the community to quit. If you live in Hong Kong, are at least 18 years old, and have been smoking daily for the past three months, you might be eligible to participate. You’ll also need to be able to communicate in Chinese and have a smartphone with a messaging app.
If you join the study, you can expect to receive support through this brief intervention aimed at helping you quit smoking. However, if you’re already in another smoking cessation program or using any medications to help quit, you won’t be able to participate. The trial is currently recruiting participants, so it’s a great opportunity to get support in your journey to quit smoking!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Hong Kong residents aged 18 years or above
- • 2. Smoke cigarette or heated tobacco product or e-cigarette daily in the past 3 months
- • 3. Exhaled carbon monoxide level ≥4 parts per million or a positive salivary cotinine test
- • 4. Able to communicate in and read Chinese
- • 5. Own a smartphone with a mobile instant messaging app installed
- Exclusion Criteria:
- • Participating in another smoking cessation programme or using any smoking cessation drug or nicotine replacement therapy
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, Hong Kong
Patients applied
Trial Officials
Tzu Tsun Luk, PhD, RN
Principal Investigator
The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported